BioCentury
ARTICLE | Finance

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

May 7, 2012 7:00 AM UTC

Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) gained $1.33 (11%) to $13.77 last week after FDA accepted for review an NDA for lomitapide to treat homozygous familial hypercholesterolemia. The PDUFA date is Dec. 29.

Alexza Pharmaceuticals Inc. (NASDAQ:ALXA) lost $0.12 (20%) to $0.49 on Friday after FDA issued a complete response letter for an NDA for inhaled Adasuve Staccato loxapine to treat agitation in patients with schizophrenia or bipolar disorder. FDA identified manufacturing deficiencies at the company's Mountain View, Calif., plant, which the company said it believes are "medical device specific and readily addressable." The agency did not identify any clinical or safety issues. Alexza lost $0.11 (18%) on the week...